Q2 FY2026 EarningsQ2 FY26 results were mixed with a slight revenue beat and significant EPS miss. Revenue reached $265.8M vs. $262.3M expected, driven by 12% growth in Automation Enabling Technologies. However, GAAP Diluted EPS of $0.30 missed the $0.56 consensus by 46% due to high SG&A and $12.5M in restructuring and acquisition costs. Management announced the $1.2B acquisition of Riverpoint Medical, significantly shifting the company's leverage and medical market exposure.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Novanta(NOVT) the Revenue is 265.81 M (+10.27%), Beat estimate;the EBIT is 47.48 M (+16.78%), Beat estimate;the EPS is 0.3 (+150%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.27B10.27%
0.26B8.82%
+0.00B1.45%
EBITExceed expectations
0.05B16.78%
0.05B11.30%
+0.00B5.48%
EPSMiss expectations
0.3150.00%
0.555362.50%
-0.2550212.50%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf